QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Regenicin, Inc. (RGIN) is “One to Watch” 0 comments
    Jun 3, 2011 5:47 PM | about stocks: RGIN

    Regenicin, Inc. is a biotechnology company with corporate headquarters in Little Falls, New Jersey. The Company specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs.

    Founded in 2010, Regenicin is playing a vital role in the development of the therapeutic candidate, PermaDerm™. This is an innovative technology that uses a patient’s own skin cells to generate living, tissue-engineered skin for the treatment of catastrophic burns. Regenicin, Inc. is now working to bring PermaDerm™ to market.

    The Company’s business model is to identify promising new therapeutic candidates that address unmet needs in growing markets. They will then look to develop the most strategic, economical and expeditious pathways for achieving regulatory approval by the FDA. Furthermore, they look to create a commercialization pipeline for bringing these new candidates to market once FDA approved.

    PermaDerm™ consists of cultured fibroblast and kerotinocytes on an absorbable collagen substrate (biomedical polymer). This produces a living skin substitute that contains epidermal and dermal components. In preclinical studies this model has been shown to generate a functional skin barrier and in clinical studies to promote closure and healing of burns.

    With the PermaDerm™ technology, a small harvested section of the patient’s own skin can be grown to graft an area one hundred times its size in as little as thirty days. PermaDerm™ is undergoing development to be the only tissue-engineered skin prepared from autologous (patient’s own) skin cells consisting of epidermal and dermal layers. The intention of this living, self-to-self skin graft tissue is to form permanent skin tissue that the immune system of the patient will not reject.

    Regenicin, Inc. is currently working with their contract manufacturer to prepare for pre-market approval of PermaDerm™ from the FDA. PermaDerm™ shows promise to save lives, reduce healthcare costs by decreasing a patient’s stay in the Critical Care Unit and reduce the need for additional surgeries. The PermaDerm™ technology has undergone clinical testing in more than 150 pediatric, catastrophic burn patients.

    Regenicin’s contract manufacturer, Lonza Biosciences, at their cGMP facility in Walkersville, Maryland, will produce PermaDerm™ and related product candidates. Upon approval by the FDA, the product candidates will ship directly to the treating physicians with all the materials needed to treat catastrophic burn patients.

    Regenicin, Inc. continues to work to develop other cell therapy technologies. They have a priority focus to develop future therapeutics in the diabetes and chronic wounds (including ulcers) areas. Their priority focus is also to develop adult stem cell therapies and reconstructive surgery applications.

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Stocks: RGIN
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.